Mega-deals drive Q1 digital health funding to $4B
Digital health companies secured $4 billion in funding in Q1 2026, marking a $1 billion increase from the previous year. This surge was primarily fueled by 12 "mega-deals," each exceeding $100 million, including significant investments in Whoop, Talkiatry, and OpenEvidence. Despite geopolitical risks and market volatility, growth was observed in AI and direct-to-consumer digital health sectors, alongside a rise in mergers and acquisitions.
GE HealthCare stock: Undervalued gem in volatile markets?
This article examines GE HealthCare (US36266G1076) as a potential investment opportunity amidst market volatility, highlighting its core business in medical imaging, diagnostics, and patient monitoring. It analyzes the company's financial health, market position against competitors like Siemens Healthineers and Philips, and its focus on innovation and global reach. The piece also discusses analyst views, investor relevance, and potential risks, concluding that GE HealthCare could be an undervalued gem for long-term investors seeking defensive growth.
Citi Maintains GE HealthCare Technologies(GEHC.US) With Hold Rating, Cuts Target Price to $80
Citi has reiterated its Hold rating on GE HealthCare Technologies (GEHC.US) but has revised its price target downwards from $84 to $80. This adjustment reflects an updated outlook from the analyst following a review of the company's financial prospects and market conditions.
Citigroup Adjusts GE Healthcare Technologies PT to $80 From $84, Maintains Neutral Rating
Citigroup has adjusted its price target for GE Healthcare Technologies (GEHC) from $84 to $80, while maintaining a Neutral rating on the stock. This update comes as part of ongoing analyst evaluations for the medical technology company. Other recent news includes Evercore ISI's adjustment to $85 and various company announcements about FDA clearances, acquisitions, and collaborations.
GE HealthCare (GEHC) receives FDA clearance for Photonova Spectra CT system
GE HealthCare has announced that its innovative Photonova Spectra CT system has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This next-generation computed tomography (CT) system aims to enhance diagnostic accuracy and patient care by improving image quality and operational efficiency. The clearance allows the company to bring its latest advancements in medical imaging to the U.S. market.
Here's Why We're Watching Pulsenmore's (TLV:PLSM) Cash Burn Situation
This article analyzes Pulsenmore's cash burn situation, highlighting its cash runway and ability to raise additional capital. As of December 2025, Pulsenmore had a cash runway of 2.1 years, based on its ₪69m cash reserves and ₪33m annual cash burn. While its reduced cash burn is encouraging, the company's annual burn of 50% of its market capitalization suggests that raising more capital could be challenging.
GE HealthCare rises after Q1 beat; cuts outlook on tariff impact
The provided article content is empty. Therefore, a summary cannot be generated at this time.
Stryker Corporation (SYK) stock price, news, quote and history
This article provides comprehensive financial information for Stryker Corporation (SYK), a medical technology company. It includes real-time stock data, historical performance, key financial metrics, earnings trends, and analyst insights. The company operates globally in medical devices, specializing in MedSurg, Neurotechnology, and Orthopaedics segments.
ANGO shares rise in pre-market after surpassing Q3 earnings estimates, though gross margin declines
AngioDynamics, Inc. (ANGO) reported an adjusted loss per share of $0.07 for Q3 fiscal 2026, exceeding analyst estimates, and saw an 8.9% increase in revenue to $78.4 million. The growth was driven by strong sales in its Med Tech segment, particularly Auryon, mechanical thrombectomy products, and NanoKnife. Despite these positive results and an updated fiscal 2026 guidance with increased net sales projections, the company experienced a decline in pro forma gross margin and continues to report adjusted operating losses.
BD Rolls Out Next-Gen Medication Dispensing System Across Europe
BD has launched its BD Pyxis Pro Dispensing Solution and BD Incada Connected Care Platform in Europe, combining automation with AI-powered insights to enhance medication management, streamline workflows, and improve patient care. This system aims to boost operational efficiency and medication availability across European hospitals. Despite a recent stock dip, the company expects this move to strengthen its competitive position in the digital healthcare sector due to increased demand for its innovative solutions.
GE HealthCare Wins FDA Nod for True Definition DL Deep Learning CT Tool
GE HealthCare has received FDA 510(k) clearance for its True Definition DL, a new deep learning image reconstruction solution for CT scans. This technology builds on existing innovations to improve image clarity and processing speed for pulmonary, musculoskeletal, and inner ear imaging. It utilizes advanced neural networks to deliver sharper images and improved detectability, enhancing diagnostic confidence without compromising dose efficiency.
Evercore Maintains GE HealthCare Technologies(GEHC.US) With Buy Rating, Cuts Target Price to $85
Evercore has reiterated its Buy rating on GE HealthCare Technologies (GEHC.US) but has adjusted its target price downwards to $85. This indicates a continued positive outlook on the company despite a moderated price expectation.
Evercore ISI Adjusts GE Healthcare Technologies PT to $85 From $98, Maintains Outperform Rating
Evercore ISI has adjusted its price target for GE Healthcare Technologies (GEHC) to $85 from $98, while continuing to maintain an Outperform rating on the stock. This update comes alongside recent news regarding GE HealthCare, including a recommendation to avoid a mini-tender offer and expansion of collaborations in medical imaging. The company's stock currently sits at $70.35 with recent changes noted.
Asia Pacific Pharmacy Automation Market Is Going to Boom |• Omnicell • McKesson Corporation
Worldwide Market Reports has released a new research study on the "Asia Pacific Pharmacy Automation Market," forecasting its growth from 2026 to 2033. The report offers an in-depth analysis of market drivers, challenges, competitive landscape, and segmentation, utilizing both primary and secondary research. Key players like Omnicell and McKesson Corporation are highlighted, and the study provides insights for stakeholders to make informed investment decisions.
GE HealthCare to announce first quarter 2026 results on April 29, 2026
GE HealthCare (Nasdaq: GEHC) will release its first quarter 2026 financial results before market open on Wednesday, April 29, 2026. Following the release, the management team will host a conference call and webcast at 8:30 a.m. Eastern Time. The earnings release, financial information, and webcast replay will be available on the GE HealthCare Investor Relations website.
GE HealthCare sets April 29 webcast for first-quarter results
GE HealthCare (Nasdaq: GEHC) announced it will release its first-quarter 2026 financial results before market open on Wednesday, April 29, 2026. The management team will also host a conference call and live webcast at 8:30 a.m. Eastern Time on the same day to discuss the results. The earnings release and webcast replay will be available on the company's Investor Relations website.
Assessing Baxter (BAX) Valuation After Launch Of IV Verify Line Labeling System
Baxter International recently launched its IV Verify Line Labeling System, an automation tool for IV line identification, medication safety, and nurse workflow. Despite this innovation and a 5.6% gain in the last 7 days, the stock has experienced a 41.0% loss over the past year. Simply Wall St's analysis suggests Baxter is currently undervalued by 23% with a fair value of $21.63, driven by ongoing portfolio optimization, cost reductions, and new leadership, but potential risks from margin pressures and product issues remain.
GE HealthCare (GEHC) Receives FDA Clearance for Photonova Spectra CT System
GE HealthCare has received FDA 510(k) clearance for its Photonova Spectra CT system, a next-generation photon-counting computed tomography system. This system utilizes proprietary Deep Silicon detector technology and Nvidia accelerated computing to provide significantly higher spatial and spectral resolution for diagnostic imaging. The company is now preparing for full commercial availability in the US to address increasing diagnostic demands.
GE HealthCare (GEHC) Receives FDA Clearance for Photonova Spectra CT System
GE HealthCare (GEHC) has received FDA 510(k) clearance for its Photonova Spectra CT system, a next-generation photon-counting computed tomography system. This system utilizes proprietary Deep Silicon detector technology to provide higher spatial and spectral resolution than conventional CT scanners, processing data up to 50 times faster. Following this clearance, GE HealthCare is preparing for full commercial availability in the US to address growing diagnostic needs.
Stocks to Avoid Under $10: iHeartMedia, Energy Recovery, Neogen Analysis | 2026 - News and Statistics
StockStory identifies three specific stocks priced under $10 to avoid in 2026: iHeartMedia (IHRT), Energy Recovery (ERII), and Neogen (NEOG). The firm cautions investors about the speculative nature of low-priced stocks and points out factors like below-sector revenue growth, diminishing returns on capital, and dilution risks for these companies. The article provides a brief analysis of each company's financial health and market position.
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Alto Neuroscience, Inc. (ANRO)
This article highlights bullish analyst ratings for two healthcare companies: Boston Scientific (BSX) and Alto Neuroscience, Inc. (ANRO). Jefferies maintained a Buy rating on Boston Scientific with a $110.00 price target, and a Strong Buy consensus, while Alto Neuroscience also received a maintained Buy rating from Jefferies with a $35.00 price target, backed by a Strong Buy consensus. The article features insights from analysts Matthew Taylor and Andrew Tsai, noting their success rates and average returns.
FDA Grants 510(k) Clearance to GE HealthCare's True Definition DL Software
GE HealthCare has received 510(k) clearance from the FDA for its True Definition DL software, a deep learning solution designed to enhance spatial resolution and suppress artifacts in CT imaging. This technology aims to deliver high-resolution images for improved diagnostic accuracy, especially in pulmonary, musculoskeletal, and inner ear imaging. It builds upon GE HealthCare's existing deep learning portfolio, addressing the growing demand for fast, precise imaging in the face of rising chronic diseases.
The GE Renaissance: A Deep Dive into the Aerospace Powerhouse (2026 Research Report)
This report details the successful transformation of GE Aerospace into a streamlined, high-margin, pure-play aviation powerhouse following the spin-offs of GE HealthCare and GE Vernova. It highlights the company's "razor and blade" business model, dominance in narrow-body propulsion, and impressive financial and stock performance. Despite risks like Boeing's production issues and high valuation, GE Aerospace is positioned as a leading investment due to its strong backlog, operational excellence, and technological leadership in sustainable engines.
Stryker Corporation (SYK) stock price, news, quote and history
This page provides a comprehensive overview of Stryker Corporation (SYK), a medical technology company. It includes current stock performance, historical data, financial metrics, and analyst insights. The company operates in MedSurg & Neurotechnology and Orthopaedics segments, offering a wide range of medical devices.
A Look At GE HealthCare Technologies (GEHC) Valuation After FDA Clearance For Photonova Spectra CT System
GE HealthCare Technologies (GEHC) received U.S. FDA 510(k) clearance for its Photonova Spectra photon-counting CT system, a move expected to boost the company's valuation. Despite recent weak share price performance, analysts believe GE HealthCare is undervalued at $93.47 per share against a current price of $71.98, citing a strong pipeline of new high-impact products. Investors are advised to consider potential tariff and China policy risks, as well as the drag from lower free cash flow.
Aberdeen Group plc Increases Holdings in Abbott Laboratories $ABT
Aberdeen Group plc increased its stake in Abbott Laboratories (ABT) by 1.2% in Q4, acquiring an additional 23,817 shares, bringing its total holding to 1,993,536 shares valued at approximately $249.8 million. Institutional investors now own about 75.18% of the company. Despite some insider selling, Director Daniel J. Starks bought 10,000 shares. Abbott reported Q4 EPS in line with expectations and issued Q1 and FY 2026 guidance, while analysts maintain a "Moderate Buy" rating with a consensus price target of $135.68.
AI scribes deliver modest time savings, but still boost clinician experience
A new study found that AI scribes offer modest time savings for clinicians, reducing EHR and documentation time by approximately 13.4 and 16 minutes respectively. While not leading to significant reductions in work hours, the technology notably improves the clinician experience by allowing more focused patient interaction. The study, involving five health systems, also highlighted that benefits vary by clinician characteristics, with primary care specialists, advanced practice clinicians, and female clinicians experiencing the greatest impact.
GE HealthCare and Collegium Pharmaceutical Stocks Trade Down, What You Need To Know
GE HealthCare and Collegium Pharmaceutical stocks fell following reports that the US might impose up to 100% tariffs on imported branded and patented drugs, particularly affecting companies that haven't negotiated lower prices. This news caused a significant sector-wide sell-off. While Collegium Pharmaceutical's shares showed volatility, the market views the news as significant but not fundamentally altering the company's long-term perception.
GE HealthCare Technologies Inc. stock falls Thursday, underperforms market
GE HealthCare Technologies Inc. (GEHC) saw its stock decline by 2.22% on Thursday, closing at $70.35. This performance was in contrast to a mixed market day, where the S&P 500 Index rose slightly while the Dow Jones Industrial Average fell. The drop broke a two-day winning streak for GE HealthCare.
Here’s why investing in NeuroPace shares could be a smart addition to your portfolio at this time
NeuroPace, Inc. shows strong growth potential due to robust RNS technology adoption, expanding referral networks, and the integration of AI solutions, plus a significant long-term opportunity with its pursuit of an indication for idiopathic generalized epilepsy (IGE). While short-term profitability may be affected by increased investments and seasonal trends, the company's core RNS business is expected to drive near-term growth, with forecasts of 20%-22% annual growth. Investor sentiment is further supported by analyst upgrades and consistent earnings beats.
Here’s why investing in NeuroPace shares could be a smart addition to your portfolio at this time
NeuroPace, Inc. is positioned for growth thanks to strong adoption of its RNS technology, expansion into new indications like idiopathic generalized epilepsy (IGE), and integration of AI solutions. While significant investments and the uncertain timeline for IGE-related revenue may affect short-term profitability, the company's core RNS business is expected to drive near-term growth. Analysts have improved their sentiment for 2026, narrowing the loss-per-share estimate.
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
NeuroPace (NPCE) shows strong growth potential due to its RNS system adoption, expanding referral networks, and AI innovations, with an average earnings surprise of 24.7%. Despite near-term profitability pressures from investments and seasonality, the company's potential expansion into idiopathic generalized epilepsy (IGE) and advanced AI tools are expected to drive significant long-term growth. The article recommends adding NeuroPace stock, currently a Zacks Rank #2 (Buy), to portfolios.
GE HealthCare and Collegium Pharmaceutical Stocks Trade Down, What You Need To Know
GE HealthCare and Collegium Pharmaceutical stocks, among others, experienced a sell-off following reports that the U.S. might impose up to 100% tariffs on imported branded and patented drugs from companies that haven't negotiated lower prices. GE HealthCare (NASDAQ: GEHC) fell 2.7% and Collegium Pharmaceutical (NASDAQ: COLL) dropped 3%. Collegium Pharmaceutical has shown volatility, and despite a recent gain due to easing crude oil prices, its shares are down 28.9% year-to-date.
Herbst Group LLC Acquires New Shares in GE HealthCare Technologies Inc. $GEHC
Herbst Group LLC recently acquired a new position in GE HealthCare Technologies Inc. (NASDAQ:GEHC), purchasing 27,750 shares valued at approximately $2.276 million during the fourth quarter. This move is part of a broader trend of institutional investment, as major firms like Dodge & Cox and Capital Research have also increased their stakes, leading to institutional investors owning about 82.06% of the stock. GE HealthCare reported strong Q4 results, exceeding analyst expectations, and maintains a "Hold" consensus rating with an average target price near $92.17.
Compagnie Lombard Odier SCmA Makes New Investment in Abbott Laboratories $ABT
Compagnie Lombard Odier SCmA recently purchased 675,058 shares of Abbott Laboratories (NYSE:ABT) valued at approximately $84.6 million in the fourth quarter, making it their 25th largest holding. Abbott reported Q4 EPS in line with expectations but missed revenue targets, setting FY 2026 EPS guidance between $5.55 and $5.80. The company faces mixed analyst sentiment, with a consensus "Moderate Buy" rating, and is engaged in strategic developments while paying a quarterly dividend.
Mammography Machine Market is expected to Hit US$ 4.1 billion by 2033 | Major Companies - GE HealthCare, Hologic, Inc., PLANMED OY, Carestream Health
The global Mammography Machine Market, valued at US$ 2.6 billion in 2024, is projected to reach US$ 4.1 billion by 2033, demonstrating a CAGR of 5.1% from 2025 to 2033. This growth is driven by increasing breast cancer awareness, technological advancements, and a rising demand for early detection solutions. Key players in this market include GE HealthCare, Hologic, Inc., and FUJIFILM Holdings Corporation, with recent developments focusing on 3D tomosynthesis, AI-powered tools, and strategic acquisitions to enhance diagnostic capabilities.
bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
bioAffinity Technologies announced a 146% year-over-year surge in unit sales for its CyPath® Lung diagnostic in Q1 2026, exceeding internal projections. This growth reflects increasing physician adoption and clinical use of the noninvasive lung cancer diagnostic, addressing a large and expanding market for pulmonary nodule management and lung cancer survivor surveillance. The company is advancing further initiatives, including a large-scale clinical study and R&D pipeline for other diagnostic tests, while focusing on commercial strategy execution.
Bank Pictet & Cie Europe AG Decreases Position in Abbott Laboratories $ABT
Bank Pictet & Cie Europe AG significantly reduced its stake in Abbott Laboratories, selling over 13,000 shares in Q4, with its remaining holdings valued at $7.52 million. This move comes as Abbott reported mixed Q4 results, meeting EPS estimates but missing revenue, while providing Q1 and FY2026 guidance and announcing a quarterly dividend. The article details strategic developments for Abbott, including an investment in Whoop and integration with Flatiron’s OncoEMR, alongside a mixed sentiment from analysts regarding its stock performance.
Healthcare: Increased Clarity on Drug Pricing and Tariffs Led to a Rebound in Q1
The Morningstar Healthcare Index, after lagging due to drug pricing uncertainty and tariffs, is expected to see solid performance in 2026, driven by its defensive nature, innovation, and benefits from AI. The sector is considered undervalued overall, with healthcare plans and devices looking most attractive. AI is anticipated to significantly reduce the time required to bring new pharmaceuticals to market, benefiting biopharma.
GE HealthCare Technologies Stock: Navigating Mini-Tender Risks Amid Strong Medical Tech Momentum
GE HealthCare Technologies (NASDAQ:GEHC) has warned shareholders about a mini-tender offer from Potemkin Limited at $45.80 per share, significantly below its current market value. Despite this risk, the company is advancing in medical imaging and diagnostics, with recent FDA clearances and strategic acquisitions bolstering its position as a precision medicine leader. Analysts maintain positive targets for GE HealthCare, highlighting its strong financial performance, dividend commitment, and long-term growth potential in the medical technology sector.
GE HealthCare Technologies Stock: Navigating Mini-Tender Risks Amid Strong Medical Tech Momentum
GE HealthCare Technologies has issued a strong warning to shareholders against an unsolicited mini-tender offer from Potemkin Limited, emphasizing that the $45.80 per share price is significantly below current market value. Despite this risk, the company continues to advance in medical imaging and diagnostics, securing FDA clearances, making strategic acquisitions, and maintaining positive analyst targets. The article highlights GE HealthCare's position as a leader in precision medicine, its robust business model, and relevance for North American investors, while also outlining broader risks such as healthcare policy shifts and supply chain dependencies.
GE HealthCare Technologies Inc. stock rises Wednesday, outperforms market
GE HealthCare Technologies Inc. (GEHC) stock rose 1.12% to $71.98 on Wednesday, outperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also saw gains, rising 0.72% and 0.48% respectively. This marks the second consecutive day of gains for GE HealthCare's stock.
Here's Why You Should Retain IRTC Stock in Your Portfolio for Now
iRhythm Holdings (IRTC) is positioned for strong growth due to robust volume, primary care expansion, and EHR integration, supported by investments in AI and clinical validation. However, the company faces potential challenges from reimbursement issues, regulatory pressures, and increasing competition. Despite these headwinds, iRhythm's strong market position and innovative approach suggest reasons to retain its stock.
Every Minute Counts at Kirkland’s Kestra Medical Technologies
Kestra Medical Technologies, based in Kirkland, is saving lives with its wearable cardioverter defibrillator, the Assure system. The device has protected over 300 individuals from sudden cardiac arrest since 2021, and the company is now focusing on expanding its market reach following positive results from a four-year study. Kestra emphasizes its mission-driven culture and strives for diversity, aiming to protect a larger portion of the 850,000 U.S. patients at risk annually.
MDT Stock May Gain From FDA's Nod for Stealth AXiS Surgical System
Medtronic (MDT) recently received FDA approval for its Stealth AXiS surgical system for cranial and ENT procedures, bolstering its Neuroscience portfolio. This system unifies surgical planning, navigation, and robotics, and features an AI-enabled architecture for advanced visualization. The approval is expected to drive a rebound in MDT stock, especially given the growing demand for minimally invasive surgeries and robust long-term growth prospects for Medtronic.
Emerging Sub-Segments Transforming the Medical Device Subscription Market Landscape
The medical device subscription market is projected to reach $24.89 billion by 2030, growing at a CAGR of 22.5%, driven by remote monitoring, AI, and telehealth integration. Key players like Thermo Fisher Scientific and Medtronic are shaping the industry, with innovations like next-generation health wearables fostering personalized wellness management. The market is segmented by device type, subscription model, application, and end-user, including diagnostic, therapeutic, and monitoring devices across various medical fields.
Segmentation, Major Trends, and Competitive Dynamics in the Insulin Patch Pumps Market
The global insulin patch pumps market is projected to reach $2.55 billion by 2030, growing at a CAGR of 10.2%, driven by advancements in diabetes care technology and increased adoption of closed-loop systems. Key players like Insulet Corporation and Medtronic PLC are innovating with products like the Embecta insulin patch pump, which recently received FDA clearance. The market is segmented by type (reusable, disposable, smart, automated), mode (basal, bolus), and application (Type 1 and Type 2 diabetes), reflecting diverse patient needs and technological progress.
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Edwards Lifesciences (EW) and Palisade Bio (PALI)
Three analysts have issued bullish sentiments on healthcare companies Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Palisade Bio (PALI). Marie Thibault of BTIG reiterated a Buy rating on Abbott with a $131.00 price target. Citi analyst Joanne Wuensch assigned a Buy rating to Edwards Lifesciences with a $101.00 price target, and H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Palisade Bio with a $7.00 price target.
Aqua Metals Reports 2025 Milestone Advancements, Strategic Progress, and Continued Commercialization Momentum
Aqua Metals reported significant advancements in 2025, including the expansion of its product platform, strengthening of its balance sheet, and progress in commercializing its AquaRefining™ technology. The company refined its go-to-market strategy, advanced strategic partnerships, and achieved key technical milestones in battery recycling and critical minerals refining, positioning itself for commercial scale deployment and long-term shareholder value creation.
List of 69 Acquisitions by Medtronic (Apr 2026)
Medtronic has completed 69 acquisitions, with peak activity in 2015. The acquisitions span 13 countries and 27 sectors, notably Cardiac and Vascular Disorders and Orthopedics. Their most recent acquisition was Scientia Vascular in March 2026 for $550M.
